HLA-E and B-cell chronic lymphocytic leukemia: Selinexor significantly decreased surface expression of HLA-E on CLL cells (mean 42% reduction at 2000nM, p < 0.001) in all 16 patient samples assessed (IQR = 28% to 48% reduction at 2000 nM) (Fig. 2A, B).